Kiniksa Pharmaceuticals (KNSA) AI Stock Analysis

620 Followers

Kiniksa Pharmaceuticals

(NASDAQ:KNSA)

Select Model

Rating:77Outperform

Price Target:$108.00▲(15.77% Upside)

Action:reiterated

Date:10/29/26

KNSA scores well on fundamentals driven by rapid revenue scale, improved TTM profitability/cash generation, and an exceptionally conservative balance sheet, reinforced by a positive earnings update with raised revenue guidance and strong ARCALYST momentum. Offsetting factors are a rich valuation (high P/E) and historical volatility in profitability/cash flows, plus elevated spending guidance and pending pipeline proof points.

Positive Factors

ARCALYST commercial expansionRapid ARCALYST growth is supported by broader patient penetration, increasing physician adoption, and a growing prescriber base. These indicators suggest expanding utilization in recurrent pericarditis and provide a durable commercial foundation beyond a single quarter.

Negative Factors

Historical earnings volatilityAlthough recent profitability has improved materially, the history of losses and changing margins shows that earnings power has not been consistently stable. This volatility makes future results more dependent on sustained ARCALYST execution and disciplined investment levels.

Kiniksa Pharmaceuticals Key Performance Indicators (KPIs)

Revenue by SegmentShows how revenue is distributed across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.

Chart Insights

ARCALYST’s product revenue has become the company's growth engine—steady, accelerating quarterly gains that prompted management to lift 2026 revenue guidance—while license/collaboration income has been episodic and effectively gone, meaning future revenue now hinges on commercial execution. That’s positive: rising prescriber penetration and the largest quarter-over-quarter increase since launch validate demand, but watch gross-to-net variability, persistent underdiagnosis limiting addressable reach, and rising operating costs that could compress margins despite strong top-line momentum.

Data provided by:

The Fly

Kiniksa Pharmaceuticals (KNSA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $7.33B
Dividend Yield: ―
Average Volume (3M): 627.10K
Price to Earnings (P/E): 65.2
Beta (1Y): 0.36
Revenue Growth: 58.19%
EPS Growth: 192.34%
Country: US
Employees: 366
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Kiniksa Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokin...

How the Company Makes Money

Kiniksa primarily makes money by selling ARCALYST (rilonacept) in the United States. Revenue is generated from product sales to customers in the pharmaceutical supply chain (e.g., specialty distributors/specialty pharmacies) that dispense the therapy...

Kiniksa Pharmaceuticals Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|% Change Since:27.83%|Next Earnings Date:Mar 01, 2027

Earnings Call SentimentPositive

The call was strongly positive, characterized by raised 2026 revenue guidance, 58% year-over-year ARCALYST revenue growth, increasing market penetration, expanding prescriber adoption, improved profitability, substantial cash generation, and progress across KPL-387 and KPL-1161. The main challenges were higher operating expenses and the fact that key clinical efficacy data and KPL-1161 indication plans remain pending.

Positive Updates

Raised 2026 Revenue Guidance

Kiniksa raised its full-year 2026 revenue guidance to between $1.045 billion and $1.050 billion and expects ARCALYST to achieve over $1 billion in revenue in 2026.

Negative Updates

Higher Operating Expenses

Operating expenses increased year-over-year due to higher ARCALYST revenue, additional cost of goods sold and collaboration expenses, increased R&D investment for KPL-387 development, and additional SG&A investment to support ARCALYST commercialization.

Company Guidance

Kiniksa raised full-year revenue guidance to between $1.045 billion and $1.050 billion and expects ARCALYST to achieve over $1 billion in revenue in 2026; it expects data from the KPL-387 pivotal phase III trial in the second half of 2027, potentially launching this drug in the 2028, 2029 timeframe, and expects KPL-1161 to be in a phase I clinical trial by the end of this year. The company expects full year R&D expenses of $160 million-$170 million in 2026 and full year SG&A expenses of $270 million-$280 million in 2026.

Kiniksa Pharmaceuticals Financial Statement Overview

Summary

Strong scale-up and improved profitability in the latest TTM period (operating profit $130.5M; ~15% operating margin; net margin ~11.6%) supported by strong balance sheet strength (very low leverage: ~$7.9M debt vs ~$710.2M equity). Cash generation is currently solid (TTM FCF $197.2M; FCF/NI ~0.99), but historical earnings and cash-flow volatility (including a loss year as recently as 2024) tempers the score.

Income Statement

78Positive

Balance Sheet

90Very Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	945.96M	677.56M	423.24M	270.26M	220.18M	38.54M
Gross Profit	513.27M	370.15M	362.33M	213.74M	197.28M	29.44M
EBITDA	144.10M	90.42M	-34.46M	-14.31M	13.43M	-154.18M
Net Income	109.57M	59.01M	-43.19M	14.08M	183.36M	-157.92M
Balance Sheet
Total Assets	983.24M	763.63M	580.55M	526.32M	459.67M	232.80M
Cash, Cash Equivalents and Short-Term Investments	568.76M	414.07M	243.63M	206.37M	190.61M	182.20M
Total Debt	7.88M	9.50M	9.86M	12.26M	5.92M	6.05M
Total Liabilities	273.05M	196.03M	142.12M	87.48M	63.52M	47.76M
Stockholders Equity	710.19M	567.61M	438.44M	438.84M	396.15M	185.04M
Cash Flow
Free Cash Flow	197.20M	25.41M	25.41M	13.17M	5.70M	-146.71M
Operating Cash Flow	198.84M	25.69M	25.69M	13.30M	5.81M	-126.30M
Investing Cash Flow	-314.87M	37.67M	37.67M	-29.56M	-8.08M	128.63M
Financing Cash Flow	22.84M	12.27M	12.27M	1.50M	2.52M	5.88M

Kiniksa Pharmaceuticals Technical Analysis

Technical Analysis SentimentPositive

Last Price93.29

Price Trends

50DMA79.39Positive

100DMA73.21Positive

200DMA60.47Positive

Market Momentum

MACD3.79Negative

RSI60.78Neutral

STOCH82.36Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Positive. The current price of 93.29 is above the 20-day moving average (MA) of 82.33, above the 50-day MA of 79.39, and above the 200-day MA of 60.47, indicating a bullish trend. The MACD of 3.79 indicates Negative momentum. The RSI at 60.78 is Neutral, neither overbought nor oversold. The STOCH value of 82.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNSA.

Kiniksa Pharmaceuticals Risk Analysis

Kiniksa Pharmaceuticals disclosed 66 risk factors in its most recent earnings report. Kiniksa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Item 5. Other Information. Trading ArrangementsQ2, 2026

2.Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity SecuritiesQ2, 2026

3.Item 3. Defaults Upon Senior Securities.Q2, 2026

Kiniksa Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

KNSA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	77Outperform	$7.13B	65.24	17.27%	―	58.19%	192.34%
LQDA	72Outperform	$3.75B	26.89	149.64%	―	2233.65%	―
CORT	67Neutral	$8.70B	54.62	8.37%	―	16.02%	-59.24%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BFRI	49Neutral	$12.92M	-1.48	-127.78%	―	17.83%	73.13%
SCYX	47Neutral	$37.91M	-2.14	-21.10%	―	489.78%	45.39%
NSRX	28Underperform	$37.46M	-3.12	-158.83%	―	―	―

* Healthcare Sector Average

Performance Comparison

KNSA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KNSA	Kiniksa Pharmaceuticals Ltd. Class A	93.29	54.15	138.35%
CORT	Corcept Therapeutics	81.93	5.28	6.89%
SCYX	SCYNEXIS Inc	3.94	-1.11	-21.95%
LQDA	Liquidia Technologies	42.20	15.78	59.73%
BFRI	Biofrontera, Inc.	0.89	-0.20	-18.44%
NSRX	Nasus Pharma Ltd.	3.20	-4.35	-57.62%

Kiniksa Pharmaceuticals Corporate Events

Executive/Board Changes

Kiniksa Pharmaceuticals Elevates Ross Moat to President

Positive

Oct 22, 2026

On October 17, 2026, Kiniksa Pharmaceuticals appointed long-time executive Ross Moat as President and Chief Operating Officer, effective immediately, with Moat continuing to report to Chairman and Chief Executive Officer Sanj K. Patel. The move eleva...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026

Kiniksa Pharmaceuticals AI Stock Analysis